![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
GLASGOW: Dolutegravir Is Superior to Darunavir/Ritonavir in Treatment-Naive HIV-1 Infected Individuals: 96 Week Results From FLAMINGO
|
|
|
Reported by Jules Levin
HIV Drug Therapy Glasgow; November 2-6, 2014; Glasgow, UK
Jean-Michel Molina,1Bonaventura Clotet,2Jan van Lunzen,3Adriano Lazzarin,4Matthias Cavassini,5Keith Henry,6Valeriv Kulagin,7Naomi Givens,8Clare Brennan,9Carlos Fernando de Oliveira10
1Hôpital Saint Louis, Service des Maladies, Infectieuses et Tropicales, and University of Paris 7, Paris, France; 2Hospital Universitari Germans Trias i Pujol, HIV Unit, Irsicaixa Foundation, UAB, UVIC-UCC, Badalona, Catalonia, Spain; 3University Medical Center Hamburg-Eppendorf, Infectious Diseases Unit, Hamburg, Germany; 4IRCCS San Raffaele Via Stamira d'Ancona, Department of Infectious Diseases, Milan, Italy; 5Lausanne University Hospital, Infectious Disease Service, Lausanne, Switzerland; 6Hennepin County Medical Center, Department of Medicine, Minneapolis, MN, USA; 7Clinical Center for Prevention and Control of AIDS, Krasnodar, Russian Federation; 8GlaxoSmithKline, Clinical Statistics, Stockley Park, UK; 9GlaxoSmithKline, Infectious Diseases, Research Triangle Park, NC, USA; 10PPD, Pharmacovigilance, Morrisville, NC, USA
![Glasgow1.gif](../images/110614/111614-1/Glasgow1.gif)
![Glasgow2.gif](../images/110614/111614-1/Glasgow2.gif)
![Glasgow3.gif](../images/110614/111614-1/Glasgow3.gif)
![Glasgow4.gif](../images/110614/111614-1/Glasgow4.gif)
![Glasgow5.gif](../images/110614/111614-1/Glasgow5.gif)
![Glasgow6.gif](../images/110614/111614-1/Glasgow6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|